Incb009471
WebINCB009471 Single-Dose Plasma Concentrations (Mean ± SE) Source publication Single and Multiple Dose Pharmacokinetics of INCB9471, a Potent Single and Multiple Dose Pharmacokinetics of INCB9471,... WebJason Boer's 19 research works with 464 citations and 1,806 reads, including: S1 File
Incb009471
Did you know?
WebBackground Information: INCB9471 Preclinical studies demonstrate: --Selective for CCR5 receptor --90% IC for R5-tropic viruses = 8-10 nM --Moderate plasma protein binding free fraction = 16% --Protein-binding adjusted IC90 = 50-60 nM --Additive/synergistic in vitro for other ARVs Single and multiple dose Phase 1 studies demonstrate:
WebThis gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The protein encoded by this gene is chemotactic for skin-associated memory T lymphocytes. WebThis study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy naïve, or who are not …
WebDownload scientific diagram INCB009471 Single-Dose Plasma Concentrations (Mean ± SE) from publication: Single and Multiple Dose Pharmacokinetics of INCB9471, a Potent … WebDr. Peter Ruane earned his medical degree from University College Dublin and completed an internal medicine residency from the Mayo Clinic in Rochester, Minnesota. He completed a research and clinical fellowship in Infectious Diseases at the West Los Angeles Veterans Administration and is Board Certified in Infectious Diseases.
WebSafety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-Tropic HIV Infected Patients : Official Title: A Randomized, Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV ...
WebTato studie vyhodnocuje bezpečnost, farmakokinetiku a účinnost antagonisty CCR5 INCB009471 u pacientů infikovaných HIV-1, kteří dosud neužívali ... Registr klinických hodnocení. ICH GCP. simon knightbridge pfizerWebA Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts. simon knightbridgeWebINCB009471, an investigational CCR5 antagonist from Incyte Corporation, demonstrated good activity against CCR5-using virus in a 14-day monotherapy study [1]. Because of this agent's long half-life, it continued to thwart viral replication long after dosing stopped. simon kneen post office isle of manWebOct 24, 2006 · This study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy … simon knight facebookWebMay 22, 2013 · INCB-9471 is a selective, reversible, small-molecule CCR5 coreceptor antagonist that binds to a CCR5 binding pocket that is different from what maraviroc binds to. INCB-9471prevents viral entry by inhibiting the interaction between HIV-1 gp120 and CCR5. INCB-9471 prevents CCR5-mediated viral entry via allosteric noncompetitive … simon knight hodsonWebscriptase inhibitor), vicriviroc and INCB009471 (CCR5 inhibitors) and elvitegravir (integrase inhibitor). The potential of other compounds with new modes of action is less clear. Currently, maturation inhibitors appear promising but for other drugs, obstacles to continued development, such as the need of parenteral application simon knights bnpWebThis gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Chemokines and their receptors are important for the migration of various cell types into the inflammatory sites. This receptor protein preferentially expresses in the thymus. simon knight headteacher